RA
ALBO

Royce & Associates’s Albireo Pharma Inc ALBO Stock Holding History

Royce & Associates’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-670
Closed -$34K – 1405
2014
Q3 		$34K Hold
670
– – ﹤0.01% 1365
2014
Q2 		$43K Hold
670
– – ﹤0.01% 1387
2014
Q1 		$55K Sell
670
-663
-50% -$60.3K ﹤0.01% 1370
2013
Q4 		$92K Buy
+1,333
New +$97.7K ﹤0.01% 1361

Other funds holding ALBO

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FMA
FNY Managed Accounts New York $83.4M AUM 11.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return

Royce & Associates's ALBO Position: Q4 2014 in Review

Royce & Associates sold out of Albireo Pharma Inc (ALBO) in Q4 2014, closing a stake of 670 shares — an estimated $34K sold.

Royce & Associates first reported a position in ALBO in Q4 2013 and held it in 4 quarters. The position peaked at $92K in Q4 2013. 35 funds tracked by Wall St. Rank hold ALBO as of Q4 2014.

  • Royce & Associates reported no remaining Albireo Pharma Inc position as of Q4 2014 after selling out during the quarter.
  • Royce & Associates sold 670 Albireo Pharma Inc shares in Q4 2014, an estimated $34K.
  • Royce & Associates first reported a position in Albireo Pharma Inc in Q4 2013 and held it in 4 quarters.
  • Royce & Associates's Albireo Pharma Inc position peaked at $92K in Q4 2013.
  • 35 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2014.

Based on Royce & Associates's 13F filing for Q4 2014, filed 9 Feb 2015.